NBDHEX re‐sensitizes adriamycin‐resistant breast cancer by inhibiting glutathione S‐transferase pi

PURPOSE: Adriamycin is a novel chemotherapeutic agent of great benefit for treating breast cancer. However, adriamycin ‐resistance remains a major obstacle. The vital Glutathione transferase P1 (GSTPi) inhibitor 6‐(7‐nitro‐2,1,3‐benzoxadiazol‐4‐ylthio) hexanol (NBDHEX) has recently shown antitumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sha, Huanhuan, Zou, Renrui, Lu, Ya, Gan, Yujie, Ma, Rong, Feng, Jifeng, Chen, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028113/
https://www.ncbi.nlm.nih.gov/pubmed/36266920
http://dx.doi.org/10.1002/cam4.5370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028113/
https://www.ncbi.nlm.nih.gov/pubmed/36266920
http://dx.doi.org/10.1002/cam4.5370

Ejemplares similares